Fig. 6

risk assessment model of tumor-infiltrating cells, immune checkpoint inhibitory molecules, and drug sensitivity analysis. (A) Spearman’s correlation analysis showed that the high-risk group of patients with CD4 T cells, monocytes, and tumor-infiltrating immune cells were positively correlated, and negative correlation with hematopoietic stem cells and neutrophils. (B) Using the risk model to predict tumor-infiltrating immune cells representative results. (C and D) The risk model is associated with immune checkpoint inhibitor-related biomarkers and found that high-risk score and PLD2 (p < 0.05) and high expression were positively related to (C), and MLH1 (p < 0.05) in the lower expression of negative correlation (D). (E) The high-risk score with chemotherapy drugs such as oxaliplatin into (p = 0.00089) the lower IC50, and the high-risk score is related to the high half-inhibitory concentration (IC50) of the protease inhibitors MG.132 (p = 0.025) and NVP-TAE684 (p = 0.01)